These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 8210834)
1. The natural history of superficial bladder carcinoma. Fitzpatrick JM Semin Urol; 1993 Aug; 11(3):127-36. PubMed ID: 8210834 [No Abstract] [Full Text] [Related]
2. Intravesical therapy: does it affect the natural history of superficial bladder cancer? Lamm DL; Griffith JG Semin Urol; 1992 Feb; 10(1):39-44. PubMed ID: 1565903 [No Abstract] [Full Text] [Related]
3. Superficial bladder carcinoma. Factors affecting the natural history. Fitzpatrick JM World J Urol; 1993; 11(3):142-7. PubMed ID: 8401631 [TBL] [Abstract][Full Text] [Related]
4. [Tumors of the bladder in women. Epidemiologic and therapeutic aspects. Apropos of 40 cases]. Rabii R; el Moussaoui A; Rais H; Joual A; Debbagh A; el Mrini M; Benjelloun S Ann Urol (Paris); 1998; 32(3):166-71. PubMed ID: 9657034 [TBL] [Abstract][Full Text] [Related]
5. Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis. Huncharek M; McGarry R; Kupelnick B Anticancer Res; 2001; 21(1B):765-9. PubMed ID: 11299841 [TBL] [Abstract][Full Text] [Related]
6. High-risk superficial bladder cancer: intravesical therapy for T1 G3 transitional cell carcinoma of the urinary bladder. Pham HT; Soloway MS Semin Urol Oncol; 1997 Aug; 15(3):147-53. PubMed ID: 9394909 [TBL] [Abstract][Full Text] [Related]
7. Natural history of superficial bladder cancer. Prognostic features and long-term disease course. Heney NM Urol Clin North Am; 1992 Aug; 19(3):429-33. PubMed ID: 1636228 [TBL] [Abstract][Full Text] [Related]
8. Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guerin instillations. Lebret T; Bohin D; Kassardjian Z; Herve JM; Molinie V; Barre P; Lugagne PM; Botto H J Urol; 2000 Jan; 163(1):63-7. PubMed ID: 10604315 [TBL] [Abstract][Full Text] [Related]
9. The expression of p53 and bcl-2 in superficial bladder transitional cell carcinoma and its role in the outcome of postoperative intravesical chemotherapy. Tzai TS; Chow NH; Lin JS; Yang WH; Tong YC Anticancer Res; 1998; 18(6B):4717-21. PubMed ID: 9891547 [TBL] [Abstract][Full Text] [Related]
10. Risk factors for subsequent development of bladder cancer after primary transitional cell carcinoma of the upper urinary tract. Matsui Y; Utsunomiya N; Ichioka K; Ueda N; Yoshimura K; Terai A; Arai Y Urology; 2005 Feb; 65(2):279-83. PubMed ID: 15708038 [TBL] [Abstract][Full Text] [Related]
11. Immunoprophylactic intravesical application of bacillus Calmette-Guerin after transurethral resection of superficial bladder cancer. Librenjak D; Situm M; Eterovic D; Dogas Z; Gotovac J Croat Med J; 2003 Apr; 44(2):187-92. PubMed ID: 12698510 [TBL] [Abstract][Full Text] [Related]
12. Analysis of factors predicting intravesical recurrence of superficial transitional cell carcinoma of the bladder without concomitant carcinoma in situ. Sakai I; Miyake H; Harada K; Hara I; Inoue TA; Fujisawa M Int J Urol; 2006 Nov; 13(11):1389-92. PubMed ID: 17083389 [TBL] [Abstract][Full Text] [Related]
13. High grade superficial (G3t1) transitional cell carcinoma of the bladder treated with intravesical Bacillus Calmette-Guerin (BCG). Pansadoro V; Emiliozzi P; depaula F; Scarpone P; Pizzo M; Federico G; Martini M; Pansadoro A; Sternberg CN J Exp Clin Cancer Res; 2003 Dec; 22(4 Suppl):223-7. PubMed ID: 16767936 [TBL] [Abstract][Full Text] [Related]
14. Role of proliferative activity estimated by bromodeoxyuridine labeling index in determining predictive factors of recurrence in superficial intermediately malignant bladder tumors. Tachibana M; Miyakawa A; Nakamura K; Baba S; Murai M; Tazaki H J Urol; 1996 Jul; 156(1):63-9. PubMed ID: 8648839 [TBL] [Abstract][Full Text] [Related]
15. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial. Divrik RT; Yildirim U; Zorlu F; Ozen H J Urol; 2006 May; 175(5):1641-4. PubMed ID: 16600720 [TBL] [Abstract][Full Text] [Related]